Swiss pharmaceutical giant Novartis said Tuesday a strategic review of its eye care unit showed that Alcon can deliver strong growth, but that a possible spin-off or listing is at least two years away.
Swiss pharmaceutical giant Novartis said Tuesday a strategic review of its eye care unit showed that Alcon can deliver strong growth, but that a possible spin-off or listing is at least two years away.